We Listened to What You Want.

The newly designed PMP AWARE is a significant upgrade from the older system. It’s easier to use, with enhanced, meaningful analytics that will help you improve patient safety by detecting risks or trends.

Enhanced PMP Capabilities:

  • Timesaving NARX Score — a three digit score that corresponds to overall risk—that automatically creates a patient assessment identifying at-risk prescriptions and combinations at-a-glance, without requiring you to drill down to details
  • Generation of multiple patients’ reports in one click
  • Prescriber reports to compare your rates with other prescribers in your specialty, emailed quarterly
  • My Rx reports that detail your prescribing data for any specific time period, and can be run at any time
  • Data sharing with many other states — new states added regularly
  • Integration into your practice flow within your EHR using a single sign-on (ask your vendor for details)
  • Milligram Morphine Equivalent (MME) is automatically calculated for patient reports
  • CDC resources, including helpful fact sheets about prescription drug monitoring programs
  • Training and educational videos
"MMEs automatically calculated for patient reports" - Spell out MMEs for first time usage - Milligram Morphine Equivalent (MME)
PMP Fact Sheet
PMP Fact Sheet

Regulations Regarding Safe Prescribing of Opioids

Regulations establish basic standards and detail requirements for safe prescribing for both acute episodes and chronic, long-term pain management. Delaware regulations now limit a first-time prescription of opioids to no more than a seven-day supply for an adult patient for an acute episode. Certain procedures are required — some at the discretion of the provider — prior to prescribing, including a query of the Prescription Drug Monitoring Program (PMP), a fluid drug screening, and obtaining an informed consent from the patient.

Delaware Prescription Opioids Guidelines for Health Care Providers
Delaware Prescription Opioids Guidelines for Health Care Providers
Uniform Controlled Substances Act Regulations
Uniform Controlled Substances Act Regulations

A Signed Consent Agreement Confirms an Understanding of the Risks and Expectations.

The informed consent confirms that the patient understands the risks of opioid therapy and the drug’s potential for addiction. The document should be signed by both the prescriber and the patient and become part of the patient’s medical record.

Informed consent should include a statement that the material risks associated with taking these controlled substances include but are not limited to:

  • Sedation that may interfere with your ability to drive and operate machinery safely
  • Interference with breathing, which could become life-threatening, or urinary and bowel function (constipation) serious enough to warrant urgent medical treatment
  • Physical dependence
  • The potential for addiction, abuse, and misuse
  • Nausea, vomiting, itching, mood changes, muscle twitching, and allergic reactions
  • Injury to the fetus or unborn child in a pregnant woman
  • Overdose as a result of accidental exposure (especially in children)
  • Neonatal opioid withdrawal (for females who could be pregnant)
  • Potentially fatal overdose resulting from interactions with alcohol and other drugs
SampleSample Informed Consent
Sample Informed Consent

A Signed Treatment Agreement Confirms Expectations.

The treatment agreement confirms expectations for both the provider and the patient. The document should be signed by both the prescriber and the patient and become part of the patient’s medical record.

The Treatment Agreement (provided as an example) could include:

  • The patient’s agreement to take medications at the dosage and frequency prescribed, with a specific protocol for lost prescriptions and early refills
  • Reasons for which medication therapy may be re-evaluated, tapered, or discontinued, including, but not limited to, violation of the Treatment Agreement or lack of effectiveness
  • The requirement that all chronic pain management prescriptions are provided by a single practitioner or a limited, agreed-upon group of practitioners
  • The patient’s agreement to not abuse alcohol or use other medically unauthorized substances or medications
  • The requirement for individuals who are prescribed opioids for chronic pain management that fluid drug screens be performed at random intervals at the practitioner’s discretion, but no less than once every six months
  • Pill counts may be requested at the discretion of the provider
  • Acknowledgment that a violation of the agreement may result in action as deemed appropriate by the prescribing practitioner, such as a change in the treatment plan, a referral to a pain specialist, or a referral to an addiction treatment program
Sample Treatment Agreement
Sample Treatment Agreement

Sign up for updates and CME Credit opportunities